Lilly's blood thinner prasugrel has predicted $1.2 billion in sales in 2012 - but probably wont even come to the all important US market until late 2008/early 2009.
It is part of a partnership between Lilly and Daiichi-Sankyo and is Lilly's most important drug still in development.
It was always going to have to compete with generic Plavix (clopidogrel). But the recent Apotex coup has raised the possibility of earlier generic price erosion.
Any "me-too" would have to demonstrate real advantages to be able to command a premium price!
Source
No comments:
Post a Comment